Immune Checkpoint Blockade in Cancer Therapy
- 15 September 2015
- journal article
- viewpoint
- Published by American Medical Association (AMA) in JAMA
- Vol. 314 (11), 1113-4
- https://doi.org/10.1001/jama.2015.11929
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaThe New England Journal of Medicine, 2015
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaJournal of Clinical Oncology, 2015
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.The Journal of Experimental Medicine, 1995
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994
- CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clonesNature, 1992